If you are not happy with the results, please do another search

JSA advised SWAMIH Investment Fund – I regarding Non-Convertible Debentures issued by Sheth Creators & Sunvision Private Limited

JSA Advocates & Solicitors advised SWAMIH Investment Fund – I (“SWAMIH”), a category II alternative investment fund, managed by SBI Ventures Limited on their subscription to unlisted, unrated, senior, secured, redeemable, non-convertible debentures (“NCDs”) aggregating up to INR 179 Crores (USD 20 million), issued by Sheth Creators & Sun-vision Private Limited, a prominent real estate developer.

JSA acted as the transaction counsel for the financing leg and advised and assisted with respect to the drafting, negotiation, and execution of the financing documents, ensuring legal and regulatory compliance.

SWAMIH is a one of its kind fund, sponsored by the Ministry of Finance, Government of India. It provides last mile funding to complete construction of stalled, brownfield, RERA registered residential developments.

JSA team was led by Anish Mashruwala, Partner; with support from Srinjoy Bhattacherjee, Partner;Swarna Hardikar, Senior Associate; and Madhur Bhatt, Associate.

JSA advises on IPO of INR 650 crores of CORONA Remedies

JSA Advocates & Solicitors (JSA) advised JM Financial Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), and Kotak Mahindra Capital Company Limited in relation to the initial public offering of equity shares of CORONA Remedies Limited (“Offer”). The Offer comprised of Offer for Sale by certain shareholders of CORONA Remedies Limited including Sepia Investments Limited, Anchor Partners, Sage Investment Trust.

CORONA Remedies Limited is the India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. The Offer received an overwhelming response from investors, with the issue being subscribed over 137.04 times.

The JSA Capital Markets Team was led by Arka Mookerjee, Lead Partner; with support from Anshu Bansal and Sagar Batra, Partners; Kairav Parikh, Principal Associate; Vatsla Varandani and Bhavini Mohan, Senior Associates; and Associates; Shreya Sharma, Ayushi Pandit, Ritu R Jaiswal & Aryaman Singh.

JSA advised on the IPO of AceVector Limited

JSA Advocates and Solicitors acted as the Indian legal counsel on the Initial Public Offering (IPO) of AceVector Limited, advising the book running lead managers, IIFL Capital Services Limited and CLSA India Private Limited. The IPO comprises a fresh issue of up to ₹3,000 million and an offer for sale of up to 63,870,763 equity shares of face value ₹1 each by certain existing shareholders.

AceVector operates a diversified digital commerce ecosystem comprising Snapdeal, a value-focused lifestyle e-commerce marketplace; Unicommerce, an e-commerce enablement SaaS platform; and Stellaro Brands, an omnichannel consumer brands retailing business.

AceVector filed its Updated Draft Red Herring Prospectus-I with SEBI and the stock exchanges on 6 December 2025.

The transaction was led by Partner Madhurima Mukherjee Saha, with support from the Equity Capital Markets team comprising Partner Sagar Batra, Senior Associate Bhavini Mohan and Associates Aryaman Singh, Nidhi Prakriti, Shivani Agrawal, and Badal Singh.

JSA advised La Renon Healthcare Pvt Ltd in relation to stake acquisition in La Renon by Creador, White Oak and Siguler Guff

JSA Advocates & Solicitors advised La Renon Healthcare Private Limited (“La Renon”), an Ahmedabad-based pharmaceutical company in relation to the acquisition of stake in La Renon by Creador, White Oak and Siguler Guff.

The transaction involved the secondary sale of shares by certain existing shareholders, including the promoter.

La Renon is a leading maker of branded formulations with a strong presence in chronic therapies and a major player in the nephrology segment besides accelerating growth in central nervous system, gastroenterology, gynaecology and cardio-diabetology portfolios, with a pan-India footprint.

The JSA team was led by Partner Sidharrth Shankar with support from the Private Equity teamcomprising Partner Nandini Seth, Principal Associate Aditya Vardhan Dayal, Senior Associate Pranav Rao, and Associate Achint Johri.

The Competition team comprised of Partner & Chair Competition Law Nisha Kaur Uberoi and Partner Pranav Satyam, Senior Associate Kamal Sharma and Associates Mayank Gandhi & Tarun Katariya.

JSA advised Synova on its investment in Klearcom

JSA Advocates & Solicitors advised Synova on its investment in Klearcom, a leading a global customer experience assurance SaaS provider.

JSA’s role involved conducting due diligence on the Indian subsidiary, reviewing and commenting on the transaction documents and assisting in closing of the transaction, from an Indian law perspective.

Klearcom provides global blue-chip clients with market-leading software supported by a worldwide proprietary network that delivers automated testing and issue-resolution for international contact centres. Synova is recognised as one of Europe’s most innovative growth investors.

The JSA team was led by Partner Sidharrth Shankar with support from the Private Equity teamcomprising Partner Nandini Seth, Principal Associate Aditya Vardhan Dayal, Senior Associate Rupaly Middha & Nabarun Ray and Associates Vivek Vishwanathan and Aaryan Pandit.

The Competition team included Partner Vaibhav Choukse, Principal Associate Nripi Jolly andAssociate Yatri Shah.

Further support was provided by the Indirect Tax team, led by Partner Manish Mishra, along with Senior Associate Shubh Dixit and Counsel Ankur Mittal, and the Employment team led by Partner Sonakshi Das.

IPO of Fujiyama Power Systems

JSA Advocates & Solicitors acted as the company’s counsel on the Rs. 8,280 million IPO of Fujiyama Power Systems Limited. The IPO comprised of a fresh issue of Rs. 6,000 million and an offer for sale by the promoters of Rs. 2,280 million.

The Equity Shares of the company were listed on BSE and NSE on November 20, 2025. Motilal Oswal Investment Advisors Limited and SBI Capital Market Limited acted as the lead managers.

Fujiyama Power Systems, with its brand ‘UTL Solar’, is a manufacturer of wide variety of products (such as panels, inverters, batteries) and solution provider in the roof-top solar industry, including on-grid, off-grid and hybrid solar systems.

The transaction was led by Partner Madhurima Mukherjee Saha, supported by the Equity Capital Markets team comprising Partner Anuj Pethia, Senior Associate Ambuj Gupta, and Associates Kumar Shubham, Priyanshi Bajajand Adnan Danish.

JSA advises on the IPO of Studds Accessories

JSA acted as the Indian legal counsel on the IPO of Studds Accessories Limited advising the lead managers, IIFL Capital Services Limited and ICICI Securities Limited. The IPO comprised of an offer for sale by the promoters and certain other shareholders with a total size of Rs. 4,554.88 million. The Equity Shares of the company were listed on BSE and NSE on November 7, 2025.

Studds Accessories Limited is the largest two-wheeler helmet player in India in terms of revenue in Fiscal 2024 and also the world’s largest two-wheeler helmet player by volume in CY 2024. This is the first IPO of a motorcycle helmet and accessories manufacturer in India.

The transaction was led by Partner Madhurima Mukherjee Saha, supported by the Equity Capital Markets team comprising Partner Anuj Pethia, Senior Associate Ambuj Gupta, and Associates Shashwat Sharma, Shivani Agrawal, Prachi Jain and Zaier Ahmad.

JSA advised Forus Health Private Limited in 21% stake acquisition by Inviga Healthcare Fund

JSA Advocates & Solicitors advised Forus Health Private Limited (“Forus”) and its Co-founder & CEO in a secondary transaction involving the acquisition of a 21% stake in Forus by Inviga Healthcare Fund (“Inviga”).

Forus is a leading ophthalmic technology company renowned for its 3nethra series of eye screening devices that have screened over 22 million patients across 75 countries. Leveraging AI-driven diagnostics, its platform has served over 5 million patients worldwide, advancing early detection and accessibility in eye care. The company’s latest innovation, the 3nethra specto — a smartphone-controlled wearable digital refractor — is redefining tele-optometry and remote vision screening. Forus was recently recognised among TIME Magazine’s World’s Top 400 HealthTech Companies for its contribution to global vision care.

Inviga is developing a differentiated multi-specialty hospital platform while strategically investing in high-potential healthcare and life sciences ventures. Through its dual-track strategy of majority-led hospital roll-ups and minority investments in innovative, IP-driven enterprises, Inviga aims to accelerate scalable healthcare solutions and long-term value creation across the ecosystem.

JSA acted as the legal advisor to Forus Health and its Co-founder & CEO on this transaction.

The JSA Corporate Team comprised Partner Manuel Jose and Senior Associate Harshita Agarwal.